日期: 2025年6月23日

Shanghai, Jun 23, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). A preclinical animal study showed that the combination of dorzagliatin and sitagliptin, a DPP-4 inhibitor, improves blood glucose levels, promotes insulin secretion, and enhances GLP-1 secretion. The combination therapy was more effective than dorzagliatin alone. The blood chemistry analysis further indicates that the combination therapy has potential benefits for lipid lowering (especially LDL) (See Figure 1).Dorzagliatin is the world's first glucokinase activator independently developed by Hua Medicine, aiming to restore the imbalanced blood glucose levels in patients with type 2 diabetes by repairing the impaired function and expression of glucokinase and enhancing glucose sensitivity in patients with type 2 diabetes. Sitagliptin, a DPP4 inhibitor, improves glucose control by blocking degradation of GLP-1. This study aims to assess the impact of long-term administration of dorzagliatin and the combination of dorzagliatin/sitagliptin on glucose homeostasis in high-fat diet-induced obesity/diabetes (DIO) mice.In the study, the DIO mice were administered dorzagliatin at a dosage of 30 mg/Kg/day, or a combination of dorzagliatin (same dose) and sitagliptin (20mg/Kg/day) for 30 days. Mice on a standard diet served as controls. On day 30, the glucose levels were all reduced compared to pre-treatment, and the combination therapy was more effective than dorzagliatin alone. Dorzagliatin monotherapy promoted insulin and GLP-1 secretion, and the combination resulted in a further increase.Blood biochemical analysis showed that drug treatment significantly improved glycated serum protein (GSP) in DIO mice. Combination therapy also improved low-density lipoprotein (LDL) levels. LDL transports cholesterol to arteries, and excessive LDL can cause arteriosclerosis, myocardial infarction, stroke, and peripheral arterial diseases. These results suggest that combination therapy has potential benefits reducing blood lipids (especially LDL) while restoring glucose homeostasis, exploring possibilities for clinical medication and new indication expansion. Figure 1 Blood Biochemical 2025 ADA 893-PAnother investigator-initiated real-world study was also presented at the ADA conference. This single-center prospective observational study aimed to evaluate the short-term efficacy and underlying mechanisms of dorzagliatin in T2DM patients. Interim analysis showed significant reductions in HbA1c levels, improvements in continuous glucose monitoring parameters, and protection of β-cell insulin secretion capacity as indicated by β-cell function indices (See Figure 2). The key analysis data are as follows:HbA1c- decreased significantly from 8.1±1.2% at baseline to 7.3±1.1% at 3 months- sustained the reduction to 7.3±1.1% at 6 months (both p<0.0001).CGM metrics- TIR increased from 65.8±22.1% to 70.3±21.5% (p=0.047) at 6 months- TAR decreased from 31.8±22.7% to 25.7±21.6% (p=0.033).β-cell function index AUC_CP- improved by 10.9% at 6 months (p<0.0001)(Figure 2 improvements of glycated hemoglobin, CGM metrics, β-cell function from baseline to 6 months 2025ADA 2004-LB)These real-world clinical application cases confirm that dorzagliatin, as a GKA, can improve glucose sensitivity, regulate blood glucose levels, and improves glycemic homeostasis and β-cell function in T2DM patients, supporting GKAs' unique therapeutic position in diabetes management, distinct from conventional hypoglycemic agents. Researchers will continue to evaluate the long-term efficacy of dorzagliatin and the long-term effects of pancreatic function preservation through follow-up.Additionally, Hua Medicine was again invited to the official ADA TV channel during the ADA conference to present a series of films discussing the global diabetes management landscape and the clinical application value of dorzagliatin in various fields.Hua Medicine will continue to conduct preclinical and clinical research, and through extensive cooperation with clinicians, further explore the clinical application potential of dorzagliatin to expand the Company's future product pipeline and disease areas.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsWebsite: ir@huamedicine.comMediaWebsite: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com.

上海 ，2025年6月23日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552.HK）今天宣布，第85届美国糖尿病协会（ADA）科学年会上，公司展示了其全球首创新药葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin）的最新研究成果。一项基础动物研究表明，多格列艾汀联合DPP-4抑制剂西格列汀（Sitagliptin）使用可以改善血糖水平、促进胰岛素分泌、增强GLP-1分泌等，效果优于多格列艾汀单独用药。血液生化分析则显示，联合用药对于降低血脂（特别是LDL）有潜在获益（见图1）。多格列艾汀是华领医药自主研发的全球首创葡萄糖激酶激活剂，通过修复2型糖尿病患者受损的葡萄糖激酶（GK）功能和表达，提升2型糖尿病患者的葡萄糖敏感性，从而改善患者血糖稳态失调。西格列汀（Sitagliptin）是一款DPP-4抑制剂类降糖药，通过抑制GLP-1降解改善血糖控制。该研究旨在评估两药联用长期治疗对高脂饮食诱导肥胖/糖尿病(DIO)小鼠葡萄糖稳态的影响，为临床联合用药提供依据。研究对于DIO小鼠模型分别给予30 mg/kg/天的多格列艾汀单药或联合20 mg/kg/天的西格列汀治疗30天，以标准饮食小鼠作为对照。治疗30天后，小鼠血糖水平较治疗前显著改善，且联合用药治疗效果优于单独用药。多格列艾汀单独用药可促进胰岛素和GLP-1的分泌，联合用药进一步增强了这一效应。血液生化指标分析则显示，药物治疗显著改善了DIO小鼠的糖化血清蛋白（GSP），联合治疗还改善了低密度脂蛋白（LDL）水平。低密度脂蛋白将胆固醇运送至动脉，过量的低密度脂蛋白会造成动脉硬化、心肌梗塞、中风及周围动脉疾病等。这一结果表明，联合用药在恢复血糖稳态的同时，对于降低血脂（特别是LDL）有潜在获益，为临床用药和新适应症的拓展探索了可能性。（图1 血液生化指标 2025 ADA 893-P）另一项研究者发起的真实世界研究也在ADA年会上进行了展示。该研究是一项单中心前瞻性观察性研究，旨在评估多格列艾汀在2型糖尿病患者中的短期疗效及机制。中期分析显示，患者的糖化血红蛋白（HbA1c）水平显著降低，连续血糖监测（CGM）指标改善，β细胞功能指标分析提示β细胞的胰岛素分泌功能得到保护(见图2)。重点分析数据如下：HbA1c：- 治疗3个月后，从基线水平8.1±1.2%显著降至7.3±1.1%，6个月时维持该水平（均p<0.0001），提示血糖长期控制效果显著CGM指标：- 目标范围内时间（TIR, Time in Range）：6个月时，从65.8±22.1%升至70.3±21.5（p=0.047），表明血糖在目标区间（通常3.9-10.0 mmol/L）的时间占比增加- 高于目标范围时间（TAR, Time above Range）:≥10.0 mmol/L从31.8±22.7%降至25.7±21.6%（p=0.033），提示高血糖持续时间缩短β细胞功能指标（AUC_CP）：- 6个月时，改善了10.9% (p<0.0001) （图2 从基线到6个月时糖化血红蛋白、持续葡萄糖监测指标及β细胞功能的改善2025ADA 2004-LB）这些真实世界的临床应用案例证实了多格列艾汀作为GKA可以直接改善葡萄糖敏感性，改善2型糖尿病患者的血糖水平，恢复患者的血糖稳态和显著改善β细胞功能，支持了GKA在糖尿病管理中不同于传统降糖药的独特治疗地位。研究者还将通过随访继续评估多格列艾汀的长期疗效，评估胰岛功能保护的长期效应。此外，华领医药再次受邀于ADA年会期间，在官方电视频道ADA TV报道系列影片，讲述全球糖尿病管理格局，以及多格列艾汀在不同领域的临床应用价值。华领医药将继续开展基础研究和临床研究，同时通过与临床医生的广泛合作，进一步探索多格列艾汀的临床应用潜力，拓展公司未来产品管线和疾病领域。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁®（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁®已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com Copyright 2025 亚太商讯 via SeaPRwire.com.

- New digital infrastructure project development company- Developing more sustainable environments for next-gen data centers / digital infrastructure- Focus on Nordic region and CanadaOSLO, Norway, June 20, 2025 - (ACN Newswire via SeaPRwire.com) - BW Digital and BW ESS, international owner-operators of digital infrastructure and energy storage systems, today announced the launch of BW Velora. BW Velora Management and BoardThe new venture will focus on developing and commercializing high-value sites for next-generation digital infrastructure and data centers in the Nordic region and Canada.In an era where data is a strategic asset, building secure, sovereign digital infrastructure is critical to reducing dependency on foreign jurisdictions and safeguarding sensitive data.Building data centers requires significant investment in critical infrastructure, which also enables the growth of other related industries.BW Velora will leverage the digital infrastructure expertise of BW Digital and BW ESS’ extensive experience developing energy infrastructure in Europe to position itself at the intersection of digital infrastructure development, access to renewable energy and engagement with local communities.BW Velora will create a sustainable environment for the construction of new data centers - from early-stage development to ready-to-build projects, including land and utilities, regulatory approvals, design and execution services – enabling customers to unlock synergies across the value chain and significantly reduce time-to-market.BW Velora aims to drive regional industrial growth, promote innovation and accelerate sustainable development. The data centers will anchor industries such as AI, renewable energy, carbon capture and advanced digital services.It was co-founded by industry experts Paal Skoe, Nils Kristian Liveng-Ness and Christian Ekeberg, whose combined experience positions the company uniquely in the fast-growing digital infrastructure market."BW Velora is strategically positioned to meet the rapidly growing demand for digital infrastructure," said Paal Skoe, Co-founder and CEO of BW Velora. "Our innovative approach significantly reduces risks, simplifies project execution and accelerates entry into high-performance data center markets, ultimately driving substantial economic growth and sustainability in local communities."Erik Strømsø, CEO of BW ESS and BW Velora chairman commented: "The worlds of digital infrastructure and sustainable energy are increasingly intertwined. As digital power demand continues to grow, we believe it is essential to take a holistic approach to energy and digital infrastructure development.“Our investment in BW Velora is an example of this and we believe the company is uniquely positioned to take a leading role in this space, while at the same time creating local economic growth and sustainability."Ludovic Hutier, CEO of BW Digital and BW Velora director, added: “As AI continues to evolve, the convergence of data center growth and increasing power demand strongly supports BW Velora’s ambitions. Through BW Digital, we are excited to extend our investment opportunities into the Nordic region, building upon our existing digitalecosystem in Asia-Pacific and fostering meaningful synergies across industries and regions."About BW VeloraBW Velora specializes in initiating, commercializing and financing high-value sites for digital infrastructure, specifically data center projects. The company addresses the complex challenges associated with digital infrastructure development, providing comprehensive solutions from early-stage project planning through to execution and financing.Part of the BW Group ecosystem, BW Velora leverages a global industry network, including decades of experience in digital infrastructure and energy infrastructure investment, delivery and operation. To find out more, visit: https://bw-velora.com/About BW ESSBW ESS is a global energy storage owner-operator, moving with speed to develop and build market-leading energy storage projects across multiple countries.Typically working with local development partners, the business is active in the UK, Australia, Italy, Germany, and Sweden. It has more than 500MWh of operating BESS projects, with over 2.5GWh under construction and a development pipeline of about 7GW.BW ESS has a strategy to hold assets for the long-term, taking a hands-on approach to unlock value throughout the energy storage asset lifecycle.Part of BW Group, BW ESS can leverage a global industry network, as well as decades of experience in energy infrastructure investment, delivery, and operation. To find out more, visit: https://bw-ess.com/About BW DigitalPrivately-owned and carrier-neutral, BW Digital develops, builds and operates digital infrastructure. Our vision is to create a sustainable digital ecosystem for cloud and AI workloads by combining data centre and connectivity assets.BW Digital is the owner-operator of Hawaiki - a 15,000km submarine cable system connecting Australia, New Zealand, American Samoa, Hawaii and the US west coast since 2018 - and is currently building its first digital campus spanning Singapore and Indonesia. The campus includes a 120MW data centre (NDP1) in Batam, a subsea cable linking Singapore and Batam (NCC) and a terrestrial fibre network within Nongsa Digital Park (Citra Connect).Part of BW Group, BW Digital can leverage a global industry network, as well as decades of experience in energy infrastructure investment, delivery, and operation. To find out more, visit https://www.bw-digital.com/Media ContactBW VeloraNils Kristian Liveng-Ness+47 413 14 003nk@bw-velora.comBW ESSTamarindo Communicationsbwess@tamarindo.globalBW DigitalWani Diwarkar - Brand Comms Bureauwani.diwarkar@bcbureau.com.au  Copyright 2025 ACN Newswire via SeaPRwire.com.